NASDAQ:BPMC
Blueprint Medicines Corporation Stock Predictions
Currently predicting for Mon, 30 Jan 2023Trading levels for BPMC
Fibonacci Support & Resistance Levels
| Level | Price | |||
|---|---|---|---|---|
| Resistance | R3 | 48.59 | 1.70 % | |
| R2 | 48.21 | 0.91 % | ||
| R1 | 47.98 | 0.414 % | ||
| Current price: | 47.78 | |||
| Support | S1 | 47.22 | -1.18 % | |
| S2 | 46.98 | -1.67 % | ||
| S3 | 46.60 | -2.46 % |
Accumulated Volume Support & Resistance Levels
| Level | Price | |||
|---|---|---|---|---|
| Resistance | R3 | 53.04 | 11.01 % | |
| R2 | 50.19 | 5.04 % | ||
| R1 | 48.24 | 0.96 % | ||
| Current price | 47.78 | |||
| Support | S1 | 46.60 | -2.47% | |
| S2 | 46.10 | -3.52% | ||
| S3 | 45.22 | -5.36% |
BPMC Predictions History
3 years ago
NameNotImportant predicted that
BPMC
for 2019-05-03 is going
$78.05 (-1.75%)
3 years ago
zsyontekleri predicted that
BPMC
for 2019-04-08 is going
$84.11 (1.08%)
About Blueprint Medicines Corporation
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally avail... BPMC Profile
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
